GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (BOM:532296) » Definitions » Debt-to-Revenue

Glenmark Pharmaceuticals (BOM:532296) Debt-to-Revenue : 0.10 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Glenmark Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹10,792 Mil. Glenmark Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹1,517 Mil. Glenmark Pharmaceuticals's annualized Revenue for the quarter that ended in Mar. 2024 was ₹120,640 Mil. Glenmark Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.10.


Glenmark Pharmaceuticals Debt-to-Revenue Historical Data

The historical data trend for Glenmark Pharmaceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Debt-to-Revenue Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.46 0.33 0.41 0.11

Glenmark Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 - 0.41 - 0.10

Competitive Comparison of Glenmark Pharmaceuticals's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Debt-to-Revenue falls into.



Glenmark Pharmaceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Glenmark Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(10792.39 + 1516.91) / 116354.56
=0.11

Glenmark Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(10792.39 + 1516.91) / 120640.24
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Glenmark Pharmaceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals (BOM:532296) Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (BOM:532296) Headlines

No Headlines